A recent study evaluated outcomes of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients treated with R-GemOx.
DLBCL is a form of non-Hodgkin lymphoma. Lymphomas occur when cells of the immune system, B lymphocytes, grow and multiply uncontrollably. DLBCL occurs mostly in adults and is aggressive. It can start in the lymph nodes or outside of the lymphatic system in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain. Often, the first sign of DLBCL is a painless rapid swelling in the neck, armpit, abdomen, or groin caused by enlarged lymph nodes. Other symptoms include night sweats, unexplained fevers, and weight loss.
R-GemOx is a combination chemoimmunotherapy consisting of rituximab, gemcitabine, and oxaliplatin. This study was a multicenter, retrospective study evaluating 183 patients with relapsed/refractory DLBCL treated with R-GemOx.
Study Results
The overall response rates (ORR) for all patients were 45% with a complete response rate (CR) of 29%. The median event-free survival (EFS) was 2.3 months and the median overall survival (OS) was 13.5 months. Patients receiving R-GemOx without intent for autologous stem cell transplant (ASCT) or CAR-T cell therapy had an ORR of 33% and a CR of 18%. Their median EFS was 2 months and median OS was 9.5 months. Patients receiving R-GemOx as a bridge to ASCT or CAR-T had an ORR of 57% and a CR of 36%, while median EFS was 3.5 months and OS was 17.4 months. Finally, patients ages 70 years and older receiving R-GemOx had an ORR of 53% and OR of 33% with median EFS of 2.2 months and OS of 13.9 months.
To learn more about lymphoma and other rare hematologic conditions, visit https://checkrare.com/diseases/hematologic-disorders/
References:
Yamshon S, et al. Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study. American Journal of Hematology. 2025 [in press]. https://doi.org/10.1002/ajh.27630